CN101049500A - 一种氨基酸组合物 - Google Patents
一种氨基酸组合物 Download PDFInfo
- Publication number
- CN101049500A CN101049500A CN 200710080248 CN200710080248A CN101049500A CN 101049500 A CN101049500 A CN 101049500A CN 200710080248 CN200710080248 CN 200710080248 CN 200710080248 A CN200710080248 A CN 200710080248A CN 101049500 A CN101049500 A CN 101049500A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- comparative example
- wound
- burn
- glutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 125000003275 alpha amino acid group Chemical group 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims abstract description 40
- 235000016709 nutrition Nutrition 0.000 claims abstract description 24
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 15
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000035764 nutrition Effects 0.000 claims abstract description 15
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 14
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 13
- CAHKINHBCWCHCF-UHFFFAOYSA-N N-acetyltyrosine Chemical compound CC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000001014 amino acid Nutrition 0.000 claims description 46
- 229940024606 amino acid Drugs 0.000 claims description 45
- 238000002347 injection Methods 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 26
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 25
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 22
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 14
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 14
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 13
- 230000000968 intestinal effect Effects 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 11
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 11
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 11
- 239000004473 Threonine Substances 0.000 claims description 11
- 235000003704 aspartic acid Nutrition 0.000 claims description 11
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 11
- 229960000310 isoleucine Drugs 0.000 claims description 11
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 11
- 229930182817 methionine Natural products 0.000 claims description 11
- 235000013930 proline Nutrition 0.000 claims description 11
- 235000004400 serine Nutrition 0.000 claims description 11
- 229960003080 taurine Drugs 0.000 claims description 11
- 235000008521 threonine Nutrition 0.000 claims description 11
- 239000004474 valine Substances 0.000 claims description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 10
- 108010044940 alanylglutamine Proteins 0.000 claims description 10
- 235000013922 glutamic acid Nutrition 0.000 claims description 10
- 239000004220 glutamic acid Substances 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 claims description 9
- 235000004279 alanine Nutrition 0.000 claims description 9
- 229960005357 lysine acetate Drugs 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 208000034767 Hypoproteinaemia Diseases 0.000 claims description 4
- 230000037354 amino acid metabolism Effects 0.000 claims description 4
- 230000036737 immune function Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 230000008093 supporting effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 48
- 206010052428 Wound Diseases 0.000 description 33
- 208000027418 Wounds and injury Diseases 0.000 description 33
- 241000282472 Canis lupus familiaris Species 0.000 description 24
- 210000002381 plasma Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 14
- 230000009467 reduction Effects 0.000 description 12
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 11
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 11
- 229960004799 tryptophan Drugs 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- 229960003121 arginine Drugs 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 229960005261 aspartic acid Drugs 0.000 description 8
- 235000020776 essential amino acid Nutrition 0.000 description 8
- 239000003797 essential amino acid Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229960002885 histidine Drugs 0.000 description 8
- 229960002429 proline Drugs 0.000 description 8
- 229960001153 serine Drugs 0.000 description 8
- 102000007584 Prealbumin Human genes 0.000 description 7
- 108010071690 Prealbumin Proteins 0.000 description 7
- -1 Amino Acid Compound Chemical class 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 229960003767 alanine Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000029751 Amino acid metabolism disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 229960002648 alanylglutamine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000892865 Heros Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960001682 n-acetyltyrosine Drugs 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
门冬氨酸 | 1-5.0 | 异亮氨酸 | 3-10 |
苏氨酸 | 2.5-5.4 | 亮氨酸 | 5-16 |
丝氨酸 | 4.0-10 | 苯丙氨酸 | 2.5-5 |
谷氨酸 | 1-15 | 醋酸赖氨酸 | 3.0-9.0 |
脯氨酸 | 4.0-10 | 组氨酸 | 1.5-3.5 |
甘氨酸 | 0.1-8 | 精氨酸 | 6.5-15 |
丙氨酸 | 0-5 | 乙酰半胱氨酸 | 0.81-2 |
N(2)-L-丙氨酰-L-谷氨酰胺 | 8-30 | 乙酰酪氨酸 | 0.81-4 |
缬氨酸 | 5-12 | 色氨酸 | 0.9-1.6 |
甲硫氨酸 | 2.5-4 | 牛磺酸 | 0-3 |
门冬氨酸 | 3.2-4.8 | 异亮氨酸 | 6.0-9.0 |
苏氨酸 | 3.5-5.2 | 亮氨酸 | 10.4-15.6 |
丝氨酸 | 4.0-6.0 | 苯丙氨酸 | 3.0-4.5 |
谷氨酸 | 1.3-1.9 | 醋酸赖氨酸 | 5.6-8.5 |
脯氨酸 | 4.0-6.0 | 组氨酸 | 2.1-3.1 |
甘氨酸 | 2.6-3.8 | 精氨酸 | 6.9-10.3 |
丙氨酸 | 0.5-0.7 | 乙酰半胱氨酸 | 0.81-1.2 |
N(2)-L-丙氨酰-L-谷氨酰胺 | 14.4-21.7 | 乙酰酪氨酸 | 0.81-1.1 |
缬氨酸 | 7.6-11.4 | 色氨酸 | 0.9-1.3 |
甲硫氨酸 | 2.6-3.8 | 牛磺酸 | 0.8-1.2 |
观察指标 | 实施例1 | 对比实施例1 |
脏器指数胸腺指数脾脏指数T淋巴细胞转化率空白ConA(cpm)实验ConA(cpm)刺激指数(S.I)T淋巴细胞亚群CD4+CD8+CD4+/CD8+ | 0.108±0.030★0.448±0.057106.9±23.312618.1±4124.1★99.6±22.8★43.0±3.9★30.2±2.51.43±0.13★ | 0.086±0.0140.368±0.06171.0±28.23997.7±1345.959.3±23.535.3±2.530.8±2.91.18±0.08 |
组别 | 伤前 | 伤后时间(天) | |
3 | 21 | ||
对比实施例1 | 9.51±0.35 | 9.29±0.40 | 7.16±0.37★★ |
对比实施例2 | 9.47±0.30 | 9.36±0.31 | 7.09±0.26★★ |
实施例1 | 9.41±0.80 | 9.41±0.69 | 7.81±0.88★★ |
组别 | 伤前 | 伤后时间(天) | |||
3 | 7 | 14 | 21 | ||
对比实施例1 | 54.86±15.07 | 160.71±65.92★★ | 116.14±75.57★ | 51.57±20.28 | 62.00±44.38 |
对比实施例2 | 56.43±19.77 | 148.00±29.37★★ | 117.71±28.79★★ | 55.00±12.70 | 55.29±11.15 |
实施例1 | 61.71±10.21 | 150.00±29.62★★ | 88.29±37.81 | 48.71±21.02 | 39.86±14.42★ |
组别 | 伤前 | 伤后时间(天) | |||
3 | 7 | 14 | 21 | ||
对比实施例1 | 4.32±0.66 | 5.32±1.47 | 4.09±0.65 | 4.18±0.88 | 5.23±0.43★★ |
对比实施例2 | 4.33±0.76 | 5.25±0.84★★ | 4.73±0.58 | 4.95±0.60 | 4.33±0.47 |
实施例1 | 4.08±0.47 | 4.91±1.33 | 4.37±0.72 | 4.17±1.09 | 4.20±0.47 |
组别 | 伤前 | 伤后时间(天) | |||
3 | 7 | 14 | 21 | ||
对比实施例1 | 0.08±0.01 | 0.07±0.02★ | 0.05±0.02★ | 0.02±0.02★★** | 0.02±0.01★★* |
对比实施例2 | 0.08±0.01 | 0.06±0.01★★ | 0.05±0.02★★ | 0.03±0.01★★* | 0.02±0.01★★* |
实施例1 | 0.08±0.01 | 0.06±0.01★★ | 0.06±0.01★ | 0.04±0.01★★ | 0.03±0.01★★ |
组别 | 伤前 | 伤后21天 | 降低幅度 |
对比实施例1 | 147.87±18.53 | 85.16±30.81★★ | 42.4% |
对比实施例2 | 149.97±13.04 | 98.97±14.76★★ | 34% |
实施例1 | 138.68±17.82 | 90.56±24.08★★ | 34.7% |
氨基酸 | 伤前 | 伤后21天 | 氨基酸 | 伤前 | 伤后21天 |
Tau | 113.39±27.45 | 88.89±14.94 | Leu | 104.65±31.60 | 77.36±20.18 |
Asp | 11.00±2.08 | 7.22±2.77★ | Val | 130.37±40.25 | 113.18±33.76 |
Thr | 184.81±76.76 | 152.36±56.41 | Tyr | 29.38±11.39 | 17.32±4.30★ |
Ser | 99.41±26.54 | 54.79±8.91★★ | Phe | 51.26±8.91 | 49.54±8.18 |
Glu | 57.53±21.40 | 50.14±11.02 | Trp | 46.7716.33 | 25.56±6.54★ |
Gln | 608.93±127.78 | 302.35±45.56★★ | Lys | 148.57±51.61 | 73.62±15.17★★ |
Gly | 205.62±41.05 | 131.82±15.37★★ | His | 66.75±16.18 | 34.75±5.42★★ |
Ala | 412.89±140.31 | 232.26±53.98★ | Arg | 134.25±27.69 | 61.91±13.09★★ |
Cys | 14.42±3.77 | 17.92±7.66 | Pro | 138.48±51.67 | 65.19±16.09★★ |
Met | 60.41±18.51 | 47.20±15.87 | Total | 2547.23±530.68 | 1624.02±89.99★★ |
Ile | 49.98±10.54 | 42.76±10.45 |
氨基酸 | 伤前 | 伤后21天 | 氨基酸 | 伤前 | 伤后21天 |
Tau | 102.30±45.63 | 94.97±41.92 | Leu | 61.15±20.45 | 69.10±27.87 |
Asp | 9.52±2.88 | 6.71±2.64 | Val | 96.77±25.35 | 100.66±33.21 |
Thr | 106.31±56.76 | 130.13±31.05 | Tyr | 15.61±4.18 | 11.60±2.30 |
Ser | 81.16±18.92 | 67.65±12.13 | Phe | 41.97±4.96 | 52.96±14.02★ |
Glu | 44.60±12.07 | 31.31±7.76★ | Trp | 37.96±10.50 | 17.66±4.99★★ |
Gln | 608.80±87.67 | 377.14±115.86★★ | Lys | 125.61±34.78 | 83.45±16.93★ |
Gly | 165.07±28.91 | 136.31±26.02 | His | 43.43±7.82 | 30.88±11.28★ |
Ala | 329.54±121.93 | 170.82±52.28★★ | Arg | 162.60±34.80 | 55.34±12.21★★ |
Cys | 18.69±5.89 | 13.75±3.07★ | Pro | 101.80±21.23 | 48.39±15.41★★ |
Met | 70.67±8.50 | 69.25±11.59 | Total | 2254.32±383.73 | 1607.36±308.86★ |
Ile | 30.77±8.93 | 39.28±14.75 |
氨基酸 | 伤前 | 伤后21天 | 氨基酸 | 伤前 | 伤后21天 |
Tau | 112.48±34.44 | 153.21±88.62 | Leu | 77.40±10.14 | 109.52±30.11 |
Asp | 11.30±6.34 | 14.33±6.49 | Val | 100.68±16.51 | 142.05±39.27★ |
Thr | 130.75±45.45 | 161.22±41.83 | Tyr | 20.71±5.17 | 20.37±9.51 |
Ser | 83.77±23.47 | 65.04±20.08 | Phe | 42.64±6.61 | 58.85±18.73★ |
Glu | 58.91±22.39 | 60.08±18.22 | Trp | 44.52±13.74 | 37.78±14.43 |
Gln | 583.05±114.61 | 432.27±60.40★ | Lys | 126.33±34.67 | 115.26±38.51 |
Gly | 152.71±44.12 | 151.91±15.82 | His | 53.32±10.08 | 46.13±11.77 |
Ala | 337.08±73.19 | 286.94±72.10 | Arg | 113.67±42.40 | 96.35±35.75 |
Cys | 19.59±5.07 | 13.69±3.64 | Pro | 95.90±25.91 | 79.43±15.12 |
Met | 50.87±13.94 | 64.98±20.98 | Total | 2238.42±371.27 | 2160.44±411.69 |
Ile | 36.74±6.55 | 58.85±14.39★ |
组别 | 伤前 | 伤后时间(天) | |||
3 | 7 | 14 | 21 | ||
对比实施例1 | 17.01±4.61 | 41.42±8.51★★* | 36.05±11.16★★ | 42.62±12.51★★ | 39.42±12.03★★ |
对比实施例2 | 15.70±2.15 | 32.34±7.89★★ | 33.74±12.35★ | 48.31±10.03★★* | 44.52±7.18★★* |
实施例 | 16.32±2.42 | 34.03±1.77★★ | 28.64±4.97★★ | 33.10±5.98★★ | 32.24±8.78★★ |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100802483A CN100518815C (zh) | 2007-02-15 | 2007-02-15 | 一种氨基酸组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100802483A CN100518815C (zh) | 2007-02-15 | 2007-02-15 | 一种氨基酸组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101049500A true CN101049500A (zh) | 2007-10-10 |
CN100518815C CN100518815C (zh) | 2009-07-29 |
Family
ID=38781236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2007100802483A Active CN100518815C (zh) | 2007-02-15 | 2007-02-15 | 一种氨基酸组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100518815C (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011021926A1 (en) * | 2009-08-21 | 2011-02-24 | N.V. Nutricia | Regulating the amino acid pool used for the acute-phase protein synthesis |
CN102631663A (zh) * | 2012-05-02 | 2012-08-15 | 张风帆 | 一种治疗男性不育、阳痿早泄的复方氨基酸组合物及制剂 |
CN102960546A (zh) * | 2012-12-03 | 2013-03-13 | 华中药业股份有限公司 | 一种复方氨基酸颗粒及其制备方法 |
CN104548076A (zh) * | 2014-12-18 | 2015-04-29 | 安徽博格生物科技有限公司 | 一种具有增强记忆力和免疫功能的制剂 |
WO2018118957A1 (en) * | 2016-12-19 | 2018-06-28 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of muscle diseases and disorders |
CN108618993A (zh) * | 2018-07-16 | 2018-10-09 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
US10201513B2 (en) | 2016-12-19 | 2019-02-12 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
WO2019246310A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the reduction or treatment of inflammation |
WO2019246221A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders |
WO2019246225A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
WO2019246214A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of hemoglobinopathies and thalassemias |
US10660870B2 (en) | 2017-08-14 | 2020-05-26 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
CN111821272A (zh) * | 2020-08-11 | 2020-10-27 | 河北科星药业有限公司 | 犬用复方氨基酸肠溶片及其制备方法 |
CN111956644A (zh) * | 2020-08-18 | 2020-11-20 | 河北科星药业有限公司 | 一种犬用复方氨基酸肠溶胶囊及其制备方法 |
WO2021113762A1 (en) * | 2019-12-06 | 2021-06-10 | Axcella Health Inc. | Compositions and methods excluding or with reduced glutamine for the treatment of hemoglobinopathies and thalassemias |
CN114224885A (zh) * | 2020-09-09 | 2022-03-25 | 河北科星药业有限公司 | 一种复方氨基酸可溶性粉及其制备方法 |
-
2007
- 2007-02-15 CN CNB2007100802483A patent/CN100518815C/zh active Active
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011021926A1 (en) * | 2009-08-21 | 2011-02-24 | N.V. Nutricia | Regulating the amino acid pool used for the acute-phase protein synthesis |
WO2011021938A2 (en) | 2009-08-21 | 2011-02-24 | N.V. Nutricia | Regulating the amino acid pool used for the acute-phase protein synthesis |
WO2011021938A3 (en) * | 2009-08-21 | 2011-08-18 | N.V. Nutricia | Regulating the amino acid pool used for the acute-phase protein synthesis |
CN102631663A (zh) * | 2012-05-02 | 2012-08-15 | 张风帆 | 一种治疗男性不育、阳痿早泄的复方氨基酸组合物及制剂 |
WO2013163928A1 (zh) * | 2012-05-02 | 2013-11-07 | Zhang Fengfan | 一种治疗男性不育、阳痿早泄的复方氨基酸组合物及制剂 |
CN102960546A (zh) * | 2012-12-03 | 2013-03-13 | 华中药业股份有限公司 | 一种复方氨基酸颗粒及其制备方法 |
CN104548076A (zh) * | 2014-12-18 | 2015-04-29 | 安徽博格生物科技有限公司 | 一种具有增强记忆力和免疫功能的制剂 |
WO2018118957A1 (en) * | 2016-12-19 | 2018-06-28 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of muscle diseases and disorders |
US11602511B2 (en) | 2016-12-19 | 2023-03-14 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US10201513B2 (en) | 2016-12-19 | 2019-02-12 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US10238617B2 (en) | 2016-12-19 | 2019-03-26 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
CN110267655A (zh) * | 2016-12-19 | 2019-09-20 | 胺细拉健康公司 | 氨基酸组合物及肌肉疾病与病症的治疗方法 |
US10471034B2 (en) | 2016-12-19 | 2019-11-12 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US11129804B2 (en) | 2016-12-19 | 2021-09-28 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US10660870B2 (en) | 2017-08-14 | 2020-05-26 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
US10682325B2 (en) | 2017-08-14 | 2020-06-16 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
US11571404B2 (en) | 2017-08-14 | 2023-02-07 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
US11833127B2 (en) | 2018-06-20 | 2023-12-05 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
WO2019246221A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders |
US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
WO2019246225A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
WO2019246214A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of hemoglobinopathies and thalassemias |
US10973793B2 (en) | 2018-06-20 | 2021-04-13 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
CN112839712A (zh) * | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于减少或治疗发炎的组合物和方法 |
CN112839643A (zh) * | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于治疗肌肉中脂肪浸润的组合物及方法 |
US11058654B2 (en) | 2018-06-20 | 2021-07-13 | Axcella Health Inc. | Compositions and methods for the treatment of hemoglobinopathies and thalassemias |
WO2019246310A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the reduction or treatment of inflammation |
CN108618993B (zh) * | 2018-07-16 | 2021-07-27 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
CN108618993A (zh) * | 2018-07-16 | 2018-10-09 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
WO2021113762A1 (en) * | 2019-12-06 | 2021-06-10 | Axcella Health Inc. | Compositions and methods excluding or with reduced glutamine for the treatment of hemoglobinopathies and thalassemias |
CN111821272A (zh) * | 2020-08-11 | 2020-10-27 | 河北科星药业有限公司 | 犬用复方氨基酸肠溶片及其制备方法 |
WO2022032804A1 (zh) * | 2020-08-11 | 2022-02-17 | 河北科星药业有限公司 | 犬用复方氨基酸肠溶片及其制备方法 |
WO2022036800A1 (zh) * | 2020-08-18 | 2022-02-24 | 河北科星药业有限公司 | 一种犬用复方氨基酸肠溶胶囊及其制备方法 |
CN111956644A (zh) * | 2020-08-18 | 2020-11-20 | 河北科星药业有限公司 | 一种犬用复方氨基酸肠溶胶囊及其制备方法 |
CN114224885A (zh) * | 2020-09-09 | 2022-03-25 | 河北科星药业有限公司 | 一种复方氨基酸可溶性粉及其制备方法 |
CN114224885B (zh) * | 2020-09-09 | 2023-11-07 | 河北科星药业有限公司 | 一种复方氨基酸可溶性粉及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100518815C (zh) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100518815C (zh) | 一种氨基酸组合物 | |
TWI429405B (zh) | 用於靜脈營養療法的小兒胺基酸溶液 | |
JP2925326B2 (ja) | ヒトの窒素保持の促進方法 | |
CN105324114B (zh) | 虾青素抗炎增效组合 | |
CN1756543A (zh) | 肝癌发生·发展抑制剂 | |
AU2011282200B2 (en) | Anti-viral properties of Aloe vera and Acquired Immune Deficiency Syndrome (AIDS) treatment | |
JP4419390B2 (ja) | 炎症性疾患治療予防剤 | |
US20090306209A1 (en) | Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same | |
CN102066402A (zh) | 肽衍生物以及含有肽衍生物的用于促进泪液分泌的组合物 | |
EP0502313A2 (en) | Method for insuring adequate intracellular glutathione in tissue | |
EP0401056B2 (en) | Glutamine in the treatment of impaired host defences | |
CN101157726A (zh) | 亚血红素短肽化合物及在抗白内障药物制备中的用途 | |
CN1092986C (zh) | 一种用于降血脂的辅酶a口服制剂及制备方法和应用 | |
JPH03204814A (ja) | 腎不全用経口アミノ酸製剤 | |
JP2012214451A (ja) | 炎症性疾患用アミノ酸組成物 | |
JP3914585B2 (ja) | マクロファージ一酸化窒素産生亢進剤 | |
WO2021249286A1 (zh) | 一种用于免疫治疗的新药配方及其片剂结构 | |
CN1149988C (zh) | 肝病治疗药 | |
Savy | Enteral glutamine supplementation: clinical review and practical guidelines | |
WO1995022967A1 (fr) | Stimulateur de l'activite analgesique | |
US20230338408A1 (en) | Compositions Containing Adenosine Triphosphate (ATP) and Methods of Use | |
US7855181B2 (en) | Dipeptides for prevention of muscle breakdown and microbial infection | |
CN1297287C (zh) | 复方丹参氨基酸输液及生产方法 | |
WO2003017787A1 (en) | Dipeptides for prevention of muscle breakdown and microbial infection | |
CN1679914A (zh) | 还原型谷胱甘肽和依布硒啉的组合药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: BEIJING SCIECURE PHARMACEUTICAL Co.,Ltd. Assignor: Beijing Suliman Medicine Technology Co.,Ltd. Contract record no.: 2012990000380 Denomination of invention: Composition of amino acid Granted publication date: 20090729 License type: Exclusive License Open date: 20071010 Record date: 20120604 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210125 Address after: 101301 Beijing Shiqiao biopharmaceutical Co., Ltd. in Zhongbei Industrial Zone, beishicao Town, Shunyi District, Beijing Patentee after: BEIJING SCIECURE PHARMACEUTICAL Co.,Ltd. Address before: 100039, 83, Fuxing Road, Beijing, nine floor, room 536, East, Haidian District Patentee before: Beijing Suliman Medicine Technology Co.,Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Chen Ding Document name: Notice of conformity |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A combination of amino acids Effective date of registration: 20231222 Granted publication date: 20090729 Pledgee: Zhongguancun Branch of Bank of Beijing Co.,Ltd. Pledgor: BEIJING SCIECURE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023110000544 |